These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22225639)

  • 21. Identification of a sulfonamide series of CCR2 antagonists.
    Peace S; Philp J; Brooks C; Piercy V; Moores K; Smethurst C; Watson S; Gaines S; Zippoli M; Mookherjee C; Ife R
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3961-4. PubMed ID: 20627722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs.
    Hsieh PW; Chiang SZ; Wu CC; Lo YC; Shih YT; Wu YC
    Bioorg Med Chem; 2008 May; 16(10):5803-14. PubMed ID: 18407506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.
    Carter PH; Brown GD; King SR; Voss ME; Tebben AJ; Cherney RJ; Mandlekar S; Lo YC; Yang G; Miller PB; Scherle PA; Zhao Q; Decicco CP
    Bioorg Med Chem Lett; 2012 May; 22(9):3311-6. PubMed ID: 22475558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists.
    Xin Z; Zhao H; Serby MD; Liu B; Schaefer VG; Falls DH; Kaszubska W; Colins CA; Sham HL; Liu G
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1201-4. PubMed ID: 15686942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5.
    Olsson RI; Jacobson I; Boström J; Fex T; Björe A; Olsson C; Sundell J; Gran U; Öhrn A; Nordin A; Gyll J; Thorstensson M; Hayen A; Aplander K; Hidestål O; Jiang F; Linhardt G; Forsström E; Collins T; Sundqvist M; Lindhardt E; Åstrand A; Löfberg B
    Bioorg Med Chem Lett; 2013 Feb; 23(3):706-10. PubMed ID: 23260347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.
    Wang L; Hubert JA; Lee SJ; Pan J; Qian S; Reitman ML; Strack AM; Weingarth DT; MacNeil DJ; Weber AE; Edmondson SD
    Bioorg Med Chem Lett; 2011 May; 21(10):2911-5. PubMed ID: 21493064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.
    Butora G; Morriello GJ; Kothandaraman S; Guiadeen D; Pasternak A; Parsons WH; MacCoss M; Vicario PP; Cascieri MA; Yang L
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4715-22. PubMed ID: 16870431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spiroindenes and spiroindanes as antagonists of CC chemokine receptor 2: WO 2009023754.
    Carter PH
    Expert Opin Ther Pat; 2010 Feb; 20(2):283-9. PubMed ID: 20100008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor.
    Doyon J; Coesemans E; Boeckx S; Buntinx M; Hermans B; Van Wauwe JP; Gilissen RA; De Groot AH; Corens D; Van Lommen G
    ChemMedChem; 2008 Apr; 3(4):660-9. PubMed ID: 18188859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
    Xue CB; Wang A; Meloni D; Zhang K; Kong L; Feng H; Glenn J; Huang T; Zhang Y; Cao G; Anand R; Zheng C; Xia M; Han Q; Robinson DJ; Storace L; Shao L; Li M; Brodmerkel CM; Covington M; Scherle P; Diamond S; Yeleswaram S; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7473-8. PubMed ID: 21036044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists.
    Kuhn CF; Bazin M; Philippe L; Zhang J; Tylaska L; Miret J; Bauer PH
    Chem Biol Drug Des; 2007 Sep; 70(3):268-72. PubMed ID: 17718722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.
    Cai C; Kang FA; Hou C; O'Neill JC; Opas E; McKenney S; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2013 Jan; 23(1):351-4. PubMed ID: 23182090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
    Napier S; Wishart G; Arbuckle W; Baker J; Barn D; Bingham M; Brown A; Byford A; Claxton C; Craighead M; Buchanan K; Fielding L; Gibson L; Goodwin R; Goutcher S; Irving N; MacSweeney C; Milne R; Mort C; Presland J; Sloan H; Thomson F; Turnbull Z; Young T
    Bioorg Med Chem Lett; 2011 May; 21(10):3163-7. PubMed ID: 21458261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists.
    Vilums M; Zweemer AJ; Yu Z; de Vries H; Hillger JM; Wapenaar H; Bollen IA; Barmare F; Gross R; Clemens J; Krenitsky P; Brussee J; Stamos D; Saunders J; Heitman LH; Ijzerman AP
    J Med Chem; 2013 Oct; 56(19):7706-14. PubMed ID: 24028535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and anticonvulsant activity of some sulfamides.
    Gavernet L; Barrios IA; Cravero MS; Bruno-Blanch LE
    Bioorg Med Chem; 2007 Aug; 15(16):5604-14. PubMed ID: 17544673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.
    Brown GD; Shi Q; Delucca GV; Batt DG; Galella MA; Cvijic ME; Liu RQ; Qiu F; Zhao Q; Barrish JC; Carter PH
    Bioorg Med Chem Lett; 2016 Jan; 26(2):662-666. PubMed ID: 26631321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.
    Lagu B; Gerchak C; Pan M; Hou C; Singer M; Malaviya R; Matheis M; Olini G; Cavender D; Wachter M
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4382-6. PubMed ID: 17587570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in CCR2 antagonists.
    Xia M; Sui Z
    Expert Opin Ther Pat; 2009 Mar; 19(3):295-303. PubMed ID: 19441905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
    Zhang X; Hufnagel H; Markotan T; Lanter J; Cai C; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5577-82. PubMed ID: 21783361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.